Variantes genéticas y niveles séricos de la ApoA1 y ApoB100 en gestantes peruanas con preeclampsia severa

José  Pacheco Romero; Oscar  Acosta; Doris  Huerta; Marlene  Vargas; Santiago  Cabrera; Pedro  Mascaro; Moisés  Huamán; José  Sandoval; Julio  Mateus; Enrique  Gil; Ricardo  Fujita

doi:10.31403/rpgo.v70i2671

Authors

José Pacheco Romero Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Oscar Acosta Universidad Nacional Mayor de San Marcos, Facultad de Farmacia y Bioquímica
Doris Huerta Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Marlene Vargas Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Santiago Cabrera Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Pedro Mascaro Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Moisés Huamán Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
José Sandoval Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Julio Mateus Atrium Health
Enrique Gil Universidad Nacional Mayor de San Marcos, Facultad de Medicina. G.I. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE
Ricardo Fujita Universidad San Martín de Porres, Facultad de Medicina Humana, CIGBM

DOI:

https://doi.org/10.31403/rpgo.v70i2671

Keywords:

Preeclampsia, Pregnant women, Apolipoprotein A-1, Apolipoprotein B-100, Serum, Peru

Abstract

Background: Preeclampsia is a multi-organ disease that causes maternal and perinatal
morbidity and mortality, with an unclear pathophysiology and without specific
prevention methods and/or treatments. Objective: To establish the association
between variants -75 G/A in the ApoA1 gene, 2488 C/T in the ApoB100 gene, serum
levels of ApoA1 and ApoB100 and severe preeclampsia in Peruvian pregnant
women. Methods: Blood samples from pregnant women with severe preeclampsia
and healthy women (controls) were processed for DNA extraction and genotyping
with the PCR-RFLP technique. In addition, serum was analyzed to quantify ApoA1 and
ApoB100. Genotypes and alleles were compared between cases and controls, as well
as serum ApoA1 and ApoB100 levels considering genotypes. Results: No significant
differences were found between the genotypic and allele frequencies of the -75 G/A
variant in the ApoA1 gene and 2488 C/T in the ApoB100 gene of both groups. A
significant difference (p=0.039) was found when comparing serum ApoA1 in patients
with heterozygous GA genotypes, with lower average levels in severe preeclamptic
(161.37 ± 40.21) compared to controls (185.37 ± 35.38). Conclusions: Although no
association was found between the variants -75 G/A variants in the APOA1 gene and
2488 C/T in the ApoB100 gene and preeclampsia, however, serum ApoA1 levels were
significantly lower in severe preeclamptic women with GA heterozygous genotype
than in controls. Thus, we contribute to the understanding of preeclampsia in
Peruvian pregnant women.